Dario Bertossi1, Pier Francesco Nocini1, Eqram Rahman2, Izolda Heydenrych3,4, Krishan Mohan Kapoor5,6, Mauricio de Maio7. 1. Department of Oral and Maxillofacial Surgery, Policlinico G.B. Rossi, University of Verona, Verona, Italy. 2. Professor of Practice, University College London, London, UK. 3. Cape Town Cosmetic Dermatology Centre, Central Park on Esplanade, Cape Town, South Africa. 4. Division of Dermatology, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa. 5. Fortis Hospital, Mohali, India. 6. University of London, London, UK. 7. Clinica Dr. Maurício de Maio, São Paulo, Brazil.
Abstract
BACKGROUND: Both age-related and congenital volume deficiencies may be addressed through the injection of hyaluronic acid (HA) fillers. Deep injection provides structural support, more superficial fat-tissue injection mediates contouring, and superficial intradermal use of HA filler and/or onabotulinumtoxinA may be used for refinement. AIMS: To evaluate the clinical efficacy, patient satisfaction, and safety of the MD Codes approach as a proposed standardized methodology for full-face rejuvenation. METHODS: This was a retrospective, single-center study of 250 consecutive adult patients undergoing full-face rejuvenation with HA fillers (Vycross) and onabotulinumtoxinA based on the MD Codes approach. RESULTS: The mean age was 39.4 ± 11.6 years, and 80.4% were female. All patients were treated with HA filler in the midface; 89.6% were also treated in the upper face, and 63.2% in the lower face. The mean number of syringes used was 14 ± 4 (range 4-25), with more syringes typically required in older versus younger patients. All patients received onabotulinumtoxinA treatment. Mean FACE-Q Appearance-Related Psychosocial Distress score decreased from 54.3 ± 9.3 pretreatment to 36.1 ± 8.9 at 3 months post-treatment (P < .05). The most common complications were bruising (35.2%), transient soft-tissue edema (14.0%), and prolonged periorbital edema (3.6%). CONCLUSIONS: Full-face rejuvenation based on the MD Codes approach provides significant esthetic improvements, with no major safety issues observed.
BACKGROUND: Both age-related and congenital volume deficiencies may be addressed through the injection of hyaluronic acid (HA) fillers. Deep injection provides structural support, more superficial fat-tissue injection mediates contouring, and superficial intradermal use of HA filler and/or onabotulinumtoxinA may be used for refinement. AIMS: To evaluate the clinical efficacy, patient satisfaction, and safety of the MD Codes approach as a proposed standardized methodology for full-face rejuvenation. METHODS: This was a retrospective, single-center study of 250 consecutive adult patients undergoing full-face rejuvenation with HA fillers (Vycross) and onabotulinumtoxinA based on the MD Codes approach. RESULTS: The mean age was 39.4 ± 11.6 years, and 80.4% were female. All patients were treated with HA filler in the midface; 89.6% were also treated in the upper face, and 63.2% in the lower face. The mean number of syringes used was 14 ± 4 (range 4-25), with more syringes typically required in older versus younger patients. All patients received onabotulinumtoxinA treatment. Mean FACE-Q Appearance-Related Psychosocial Distress score decreased from 54.3 ± 9.3 pretreatment to 36.1 ± 8.9 at 3 months post-treatment (P < .05). The most common complications were bruising (35.2%), transient soft-tissue edema (14.0%), and prolonged periorbital edema (3.6%). CONCLUSIONS: Full-face rejuvenation based on the MD Codes approach provides significant esthetic improvements, with no major safety issues observed.
Authors: Ricardo Grillo; Alexandre M Borba; Ana Paula C B Lima; Marcos C Pitta; Regiane Veronesi; Claudio R P Jodas Journal: J Taibah Univ Med Sci Date: 2021-09-04
Authors: Dario Bertossi; Riccardo Nocini; Berend van der Lei; Philippe Magistretti; Alessandro Gualdi; Ali Pirayesh; Alberto Marchetti Journal: Plast Reconstr Surg Glob Open Date: 2021-11-24